A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab

Gershon Koshy, Andrew Hale, Dev Jaiswal, Daniel Wildes, Mousumi Som

Research output: Contribution to journalArticlepeer-review

Abstract

Immune checkpoint inhibitors (ICIs) are approved for the treatment of many different cancers.
Since their arrival, these agents have offered improved disease outcomes including a longer
duration of overall survival. [1] There does remain however several uncommon yet severe
adverse side effects from this drug class including cardiotoxicity
Original languageAmerican English
JournalOklahoma State Medical Proceedings
Volume4
Issue number3
StatePublished - 7 Dec 2020

Fingerprint Dive into the research topics of 'A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab'. Together they form a unique fingerprint.

Cite this